Sanofi's interim leadership addressed concerns regarding the defense of Dupixent's patents during a recent earnings call, clarifying that it is unrelated to CEO Paul Hudson's departure. The company aims to reassure stakeholders amidst leadership changes.
Sanofi’s interim leadership sought on a Thursday earnings call to quell concerns that its sudden defense of Dupixent’s patents had anything to do with the departure of CEO Paul Hudson.
Original title: “Sanofi defends Dupixent patents, but execs insist it has nothing to do with CEO change”